$Lineage Cell Therapeutics(LCTX.US)$Opregen® (Rg6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degen...
$Lineage Cell Therapeutics(LCTX.US)$Lineage Cell Therapeutics' RG6501 (OpRegen) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lineage Cell Therapeutics股票討論區
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degen...
暫無評論